PT  - JOURNAL ARTICLE
AU  - Ephraim E Parent
AU  - Bital Savir-Baruch
AU  - Isis W Gayed
AU  - Frankis Almaguel
AU  - Bennett Chin
AU  - Austin R Pantel
AU  - Evan Armstrong
AU  - Amanda Morley
AU  - Robin C Ippisch
AU  - Robert Richard Flavell
TI  - JNMT continuing education: <sup>177</sup>Lu PSMA therapy
AID  - 10.2967/jnmt.122.263814
DP  - 2022 Jul 01
TA  - Journal of Nuclear Medicine Technology
PG  - jnmt.122.263814
4099  - http://tech.snmjournals.org/content/early/2022/07/26/jnmt.122.263814.short
4100  - http://tech.snmjournals.org/content/early/2022/07/26/jnmt.122.263814.full
AB  - Radiopharmaceutical therapy utilizing 177Lu-PSMA is an effective treatment for prostate cancer which has recently been approved by the United States Food and Drug Administration. This method leverages the success of PSMA targeted PET imaging, enabling the delivery of targeted radiopharmaceutical therapy, This agent has demonstrated a clear benefit in large prospective clinical trials, and promises to become part of the standard armamentarium of treatment for patients with prostate cancer. In this review, the evidence supporting the use of this agent is highlighted, along with important areas now under investigation. Practical information on technology aspects, dose administration, nursing, and the role of the treating physician is highlighted. Overall, 177Lu-PSMA treatment requires close collaboration between referring physicians, nuclear medicine, technologists, radiopharmacy, and nursing, to enable streamlined patient care.